Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary myocardial involvement in systemic sclerosis.

A Kahan1, Y Allanore

  • 1Paris 5 René Descartes University, Department of Rheumatology A, Cochin Hospital, AP-HP, Paris, France. andre.kahan@cch.aphp.fr

Rheumatology (Oxford, England)
|September 19, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort.

Arthritis research & therapy·2025
Same author

Exposure to alcohol or lead? Chronic gout in baroque depictions of obese Silenus and Bacchus.

Journal of endocrinological investigation·2024
Same author

Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease.

Scientific reports·2020
Same author

Six-week antibiotic therapy after one-stage replacement arthroplasty for hip and knee periprosthetic joint infection.

Medecine et maladies infectieuses·2020
Same author

ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis.

Arthritis research & therapy·2020
Same author

Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study.

Clinical rheumatology·2019
Same journal

Use of advanced cardiovascular imaging in rheumatic immune-mediated inflammatory diseases.

Rheumatology (Oxford, England)·2026
Same journal

Comment on: Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform.

Rheumatology (Oxford, England)·2026
Same journal

Development and validation of a Relapsing Polychondritis disease-specific Quality of Life instrument (ERN ReCONNET RP-QoL).

Rheumatology (Oxford, England)·2026
Same journal

The burden of steroid use in systemic lupus erythematosus.

Rheumatology (Oxford, England)·2026
Same journal

Prognostic value of quantifying vascular inflammation through ultrasound in patients with giant cell arteritis: the MAGiCUS study.

Rheumatology (Oxford, England)·2026
Same journal

A conceptual framework for a RA probability score integrating classification criteria and point-of-care ultrasound in early arthritis.

Rheumatology (Oxford, England)·2026
See all related articles

Systemic sclerosis (SSc) affects the heart through microcirculation impairment. Treatments like vasodilators can improve heart function and blood flow in SSc patients.

Area of Science:

  • Cardiology
  • Rheumatology
  • Vascular Biology

Background:

  • Systemic sclerosis (SSc) is a connective tissue disease featuring vascular lesions and fibrosis.
  • Cardiac involvement is frequent in SSc and indicates a poor prognosis.
  • Myocardial damage in SSc is linked to impaired microcirculation and abnormal vasoreactivity.

Purpose of the Study:

  • To investigate myocardial involvement in Systemic Sclerosis.
  • To explore the role of microcirculation impairment in SSc-related cardiac dysfunction.
  • To assess the efficacy of vasodilators in treating cardiac abnormalities in SSc.

Main Methods:

  • Review of existing literature on SSc and cardiac involvement.
  • Analysis of studies using conventional methods to assess myocardial function.

Related Experiment Videos

  • Inclusion of recent findings from tissue Doppler echocardiography and MRI.

    • Main Results:

    • Myocardial perfusion impairment, systolic and diastolic left ventricular dysfunction, and right ventricular dysfunction are reported in SSc.
    • Microcirculation impairment is a key factor in SSc myocardial involvement.
    • Vasodilator therapies show potential in improving cardiac function and perfusion.

    Conclusions:

    • Cardiac involvement is a significant complication of Systemic Sclerosis.
    • Microvascular dysfunction plays a crucial role in SSc-related heart disease.
    • Pharmacological interventions targeting vasoreactivity can ameliorate cardiac abnormalities in SSc.